Ignite Creation Date:
2024-05-06 @ 6:49 PM
Last Modification Date:
2024-10-26 @ 2:55 PM
Study NCT ID:
NCT05797597
Status:
RECRUITING
Last Update Posted:
2023-04-06
First Post:
2023-03-01
Brief Title:
Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease
Sponsor:
Lucyna Mastalerz
Organization:
Jagiellonian University
Study Overview
Official Title:
Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AERD-CoV19
Brief Summary:
Aspirin-exacerbated respiratory disease AERD is characterized by the presence of asthma chronic rhinosinusitis with nasal polyposis CRwNP and acute respiratory reactions induced by aspirin and other cyclooxygenase-1 inhibitors One of the well-established therapeutic options is aspirin desensitization followed by daily aspirin therapy The potential mechanisms underlying the clinical benefit of this approach include the downregulation of CysLT1 receptor inhibition of PGD2 and interleukin IL-4 via the signal transducer and activator of transcription 6 global blood urine activation of type 2 T2 inflammation as well as local sputum reduction of T2 asthma inflammation Indeed among current aspirin-treated patients with AERD n37 no one had severe acute respiratory syndrome coronavirus clade 2 SARS CoV-2 infection and most importantly none of them developed COVID19 during pandemic WHY Notably patients with AERD did not have asthma and nasal polyps exacerbation on aspirin which is in line with other studies Respiratory infections such as the current COVID-19 pandemic target epithelial cells in the respiratory tract SARS-CoV-2 spike S protein binds angiotensin-converting enzyme 2 ACE2 and in concert with host proteases principally transmembrane serine protease 2 TMPRSS2 promotes cellular entry Nasal and bronchial epithelium play a key role in the early phases of an immune response to respiratory viruses Induced sputum IS and nasal lavage NL cells are likely the first immune cells to encounter SARS CoV-2 during an infection and their reaction to the virus will have a profound impact on the outcome of the infection Interferons IFNs are antiviral cytokines and among the first mediators produced upon viral infection IFNs are divided into three groups based on their receptor usage type I IFNs IFN-α and IFN-β type II IFN IFN-γ and type III IFNs IFN-λ1 and 2 Both production of IFN and cellular response to IFN are critical steps for the restriction of viral dissemination An interferon-stimulated gene ISG is a gene whose expression is stimulated by interferon Specifically type I and type III interferons are antiviral cytokines triggering ISGs that combat viral infections The type II interferon class only has one cytokine IFN-γ which has some antiviral activity To conclude the assessment of gene expression for interferon α1 IFNA1 interferon β1 IFNB1 interferon γ IFNG interferon λ1 and λ2 IFNL1 and IFNL2 as well as for ACE2 and TMPRSS2 in sputum and nasal cells may shed new light on the course of this infection in patient with AERD during long term aspirin therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None